Searchable abstracts of presentations at key conferences in endocrinology

ea0007p163 | Neuroendocrinology and behaviour | BES2004

Primary therapy with somatostatin analogues in acromegaly does not restore orderly GH secretion

Parkinson C , Darzy K , Peacey S , Thorner M , Veldhuis J , Trainer P , Shalet S

Tumoural GH secretion in acromegaly is characterised by increased non-pulsatile (basal) release, pulse amplitude and pulse frequency. We have studied the effect of primary therapy with Sandostatin LAR on GH pulsatility in 9 patients with acromegaly who achieved disease control (mean serum GH<2ug/L) on therapy (7 males; median (range) age 67 (43-75). Data obtained were compared with 16 healthy subjects (10 males, age 50 (30-75)). Spontaneous 24-h GH secretion (20 minute samp...

ea0006p40 | Endocrine tumours and neoplasia | SFE2003

The effect of pegvisomant therapy on plasma levels of matrix metalloproteinases 2, 9 and vascular endothelial growth factor in patients with acromegaly

Paisley A , Randeva H , Parkinson C , Alsafadi H , Roberts M , Monson J , Drake W , Trainer P

Vascular endothelial growth factor (VEGF) is involved in the activation of the matrix metalloproteinase system (MMP) which in turn degrades the extracellular matrix involved in development, morphogenesis and tissue remodelling. Increased activity of MMPs has been implicated in atherosclerosis and cardiovascular disease. This study assessed plasma MMP and VEGF levels in patients with active acromegaly (IGF-I >130%ULN), and on treatment with pegvisomant.<p class="abstext"...

ea0003p200 | Neuroendocrinology | BES2002

Disease activity in acromegaly may be assessed four weeks after discontinuation of pegvisomant

Drake W , Loureiro R , Parkinson C , Roberts M , Akker S , Monson J , Besser G , Trainer P

Patients with acromegaly treated with medical therapy intermittently discontinue therapy to allow assessment of underlying disease activity. This is particularly so in patients treated with pituitary irradiation. Typical 'washout' times include 5 weeks for bromocriptine and 2 weeks for short-acting sc octreotide; longer periods are required for cabergoline and slow-release somatostatin analogues. Pegvisomant is a novel medical therapy for acromegaly that functions as a GH rece...

ea0085p45 | Pituitary and Growth 1 | BSPED2022

The use of 6-monthly GnRH analogues in the paediatric population

Apperley Louise , Dharmaraj Poonam , Blair Joanne , Ramakrishnan Renuka , Das Urmi , Didi Mohamed , Laing Peter , Yung Zoe , Cassidy Kelly , Blundell Pauline , Jarvis Charlotte , Parkinson Jennifer , Senniappan Senthil

Background: Pubertal progression is inhibited in central precocious puberty with the use of gonadotropin releasing hormone (GnRH) analogues. They are usually given every 10 to 12 weeks via an intramuscular depot, but more recently, a 6-monthly preparation has become available for clinical use.Aim: The aim of this project was to evaluate the efficacy and acceptability of 6-monthly triptorelin, a GnRH analogue, at a tertiary children’s hospital.<p...

ea0069p62 | Poster Presentations | SFENCC2020

Breast Cancer in MEN1: Coincidence or association?

Cheah Seong Keat , Chad Bisambar , Pitfield Deborah , Giger Olivier , ten Hoopen Rogier , Martin Jose Ezequiel , Park Soo-Mi , Parkinson Craig , Challis Benjamin , Casey Ruth

Section 1: Case history: A 38 year old female was identified as carrying a heterozygous pathogenic MEN1 variant (c.13404delG) through predictive testing, following a diagnosis of familial hyperparathyroidism.Section 2: Investigations: Routine screening for hyperparathyroidism and pituitary disease was negative. However, a CT thorax–abdomen–pelvis revealed a 41 mm pancreatic tail mass. Biopsy via endoscopic ultrasound confirmed a well-d...

ea0065p150 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Breast cancer in MEN1: coincidence or association?

Cheah Seong Keat , Bisambar Chad , Pitfield Deborah , Giger Olivier , Hoopen Rogier ten , Martin Jose Ezequiel , Clark Graeme , Park Soo-Mi , Parkinson Craig , Challis Bejamin , Casey Ruth

A 38 year old female was identified as carrying a heterozygous pathogenic MEN1 variant (c.13404delG) through predictive testing, following a diagnosis of familial hyperparathyroidism. Routine screening for hyperparathyroidism and pituitary disease was negative. However, a CT thorax-abdomen-pelvis revealed a 41 mm pancreatic tail mass. Biopsy via endoscopic ultrasound confirmed a well-differentiated (grade 1) pancreatic neuroendocrine tumour (pNET) with MIB1<1%. Bi...

ea0030p18 | (1) | BSPED2012

The Euro-WABB Registry: differences in prevalence of diabetes between Wolfram, Alstrom, and Bardet-Biedl syndromes

Farmer Amy , Ayme Segolene , Maffei Pietro , Mccafferty Susan , Sinnott Richard , Mlynarski Wojciech , Nunes Virginia , Paquis Veronique , Parkinson Kay , Tillman Vallo , Barrett Timothy

Objectives: We aimed to develop a registry for the rare genetic diseases Wolfram (WS), Alstrom (AS), Bardet Biedl (BBS) and other diabetes syndromes, containing clinical, genetic diagnostic and outcome data. The purpose is to establish the natural history of these diseases; to assess clinical management; to characterize cohorts for future clinical trials; and to establish genotype phenotype relations. This abstract describes the first 50 patients recruited.<p class="abstex...

ea0013oc27 | Neuroendocrinology, reproduction and cardiovascular | SFEBES2007

Manganese-enhanced MRI demonstrates that oxyntomodulin and GLP-1 affect neuronal activity in distinct regions of the brain

Chaudhri Owais , Parkinson James , Herlihy Amy , Salem Victoria , Kuo Yu-Ting , Bell Jimmy , So Po-Wah , Dhillo Waljit , Stanley Sarah , Ghatei Mohammad , Bloom Steve

The rise in the prevalence of obesity has imparted urgency to the study of the mechanisms of appetite regulation. Oxyntomodulin (OXM) and glucagon-like peptide-1 (GLP-1) are anorexigenic gut hormones thought to act via the same receptor. There is an increasing body of evidence, however, that they may act via distinct pathways. Magnetic resonance imaging (MRI) is increasingly being used as a tool for tracking changes in neuronal activity in vivo through time. Manganese-e...

ea0095p62 | Obesity 1 | BSPED2023

Clinical characteristics and complications of excess weight (CEW) seen in multi-disciplinary tier-3 paediatric weight management services: a two centre experience

Hawton Katherine , Apperley Louise , Parkinson Jennifer , Owens Meghan , Semple Claire , Fitzgerald Amy , Easter Shelley , Clark Kate , Lund Kim , Clarke Ellie , Giri Dinesh , Senniappan Senthil , Hamilton-Shield Julian

Background: Children and young people living with severe obesity experience wide ranging complications of excess weight (CEW), however their prevalence is not well defined. We have evaluated baseline clinical characteristics and complications in two multi-disciplinary tier-3 paediatric weight management services in different regions of the UK.Methods: All new patients (n=185) aged 2–17 years seen in a 12-mo...

ea0095p66 | Obesity 1 | BSPED2023

A higher proportion of physical and mental health CEW in areas of higher socio-economic deprivation demands urgent action: Comparative data across two regions of UK

Apperley Louise , Hawton Katherine , Parkinson Jennifer , Owens Meghan , Semple Claire , Fitzgerald Amy , Easter Shelley , Clark Kate , Lund Kim , Clarke Ellie , Giri Dinesh , Hamilton-Shield Julian , Senniappan Senthil

Introduction: NCMP (National Childhood Measurement Programme) data has highlighted a higher prevalence of childhood obesity in highly deprived areas, however the prevalence of complications from excess weight (CEW) in relation to social deprivation has not been previously reported. The aim of this study is to compare the demographic data along with CEW in children and young people (CYP) with obesity being managed at two different centres in the UK, with a very...